Ignite Creation Date:
2024-05-06 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05737953
Status:
RECRUITING
Last Update Posted:
2023-02-21
First Post:
2023-02-05
Brief Title:
Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples
Sponsor:
Zhaoshen Li
Organization:
Changhai Hospital
Study Overview
Official Title:
Construction of Molecular Diagnostic Marker Models for Pancreatic Cystic Tumors Based on cfDNA Methylation Sequencing and Proteomic Analysis of Pancreatic Cystic Fluid Samples
Status:
RECRUITING
Status Verified Date:
2023-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this observational study is to test in patients with cystic tumor of pancreas The main questions it aims to answer are
Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinousnon-mucinous correlate with pathological features and find molecular features associated with the degree of malignancy
Participants will Provide post-operative cyst fluid specimens
Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinousnon-mucinous correlate with pathological features and find molecular features associated with the degree of malignancy
Participants will Provide post-operative cyst fluid specimens
Detailed Description:
Patients with pancreatic cystic tumors were divided into control mucinous tumor and non-mucinous tumor groups and cfDNA molecules and protein molecules that were significantly altered between different groups were found by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic detection techniques Multi-omics analysis was performed to construct a more efficient molecular diagnostic marker model Correlating models with pathological features to find molecular features associated with the degree of malignancy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None